elekta ab-b shs (EKTAB:Stockholm)
elekta ab-b shs (EKTAB) Snapshot
|
Open
kr101.60
|
Previous Close
kr101.40
|
|
|
Day High
kr102.40
|
Day Low
kr101.30
|
|
|
52 Week High
12/12/12 - kr105.30
|
52 Week Low
06/28/12 - kr76.63
|
|
|
Market Cap
39.2B
|
Average Volume 10 Days
1.1M
|
|
|
EPS TTM
kr2.75
|
Shares Outstanding
368.6M
|
|
|
EX-Date
09/5/12
|
P/E TM
37.1x
|
|
|
Dividend
kr1.25
|
Dividend Yield
1.22%
|
Related News
elekta ab-b shs (EKTAB) Related Businessweek News
No Related Businessweek News Foundelekta ab-b shs (EKTAB) Details
Elekta AB (publ), a medical technology company, develops and sells clinical solutions for the treatment of cancer and neurological diseases worldwide. It offers neuroscience products, including Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; The Extend program for utilization of Leksell Gamma Knife Perfexion; Elekta Axesse, an integrated stereotactic radiation therapy system, which combines 3D and 4D image guidance at the time of treatment; and Leksell Stereotactic System for functional neurosurgery and biopsies. The company’s neuroscience solutions comprise Gamma Knife surgery, a non-invasive method for treating brain disorders; stereotactic neurosurgery, an integrated solution for minimally invasive neurosurgery for the treatment of brain; and surgical navigation accessories comprising 3D-Arm, a stable platform for tools and devices, as well as Hennig Instrument Guide, a minimally invasive skull-mounted device. It also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system providing a range of energy levels and beam characteristics for intensity modulated radiation therapy; Elekta Compact, a gateway to RT for oncology centers; treatment planning systems for radiation therapy, radiosurgery, and particle therapy techniques; and oncology information systems solutions. In addition, the company offers software products, including MOSAIQ data director, which enables archiving, retrieval, and management of data; SupportPlus, a portal for installation and troubleshooting documents; IntelliLab, a laboratory information system offering tools to clinical and business operations; METRIQ and Précis-Central; and RTP software documentation. Elekta AB (publ) was founded in 1972 and is headquartered in Stockholm, Sweden.
elekta ab-b shs (EKTAB) Key Developments
Elekta AB received 510(k) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to begin shipping and installation of all components of the Versa HD(TM) system within the United States. Featuring high precision beam shaping and tumor targeting, and capable of delivering radiation doses three times faster than previous Elekta linear accelerators, Versa HD sets a higher benchmark for cancer treatment. Fully integrated with the Agility(TM) 160-leaf multileaf collimator (MLC), Versa HD provides high-definition, high-speed beam shaping over a versatile 40 X 40 cm field. This unique combination of fast MLC leaf speed with the new High Dose Rate mode empowers clinicians to fully exploit high dose rate delivery and take advanced therapies such as VMAT, SRS and SRT to new levels -- without compromising treatment times. Versa HD also features: - Safety innovations. - Customizable, disease-specific configurations. - Modern patient-friendly ergonomics. - Fewer delays and downtime with real-time remote system monitoring. - Low environmental impact, low energy consumption design.
Odense University Hospital (OUH, Odense) recently signed an order to acquire two Versa HD(TM) radiation therapy treatment systems. Elekta AB announced the global launch of Versa HD, an advanced linear accelerator designed to improve patient care and treat a broader range of cancers, and featuring ultra-conformal beam shaping and tumor targeting. Versa HD promises the versatility to enable clinicians to deliver conventional therapies to a wide range of tumors throughout the body, while also permitting treatment of very complex cancers that require extreme targeting accuracy. Versa HD also unveils new capabilities designed to maximize health care system resources and deliver highly sophisticated therapies without compromising treatment times. Versa HD incorporates technologies designed to provide an immediate impact to patient health and quality of life. Integrated with Elekta's revolutionary Agility MLC, Versa HD provides highly conformal beam shaping a critical requirement for maximizing the dose to the target while also preserving surrounding healthy tissues. Significantly, this high targeting accuracy is available over a large field-of-view, permitting delivery of high-definition (HD) beams to a broad spectrum of complex targets. Historically, high-definition beam shaping often was mechanically limited to only small target therapies. Versa HD with Agility overcomes this challenge, empowering clinicians to deliver extremely precise beam contouring for both small and large targets. Capable of delivering radiation doses three times faster than previous generation Elekta linear accelerators, Versa HD harnesses the ultra-fast leaf speeds of Agility MLC. With this groundbreaking combination, clinicians can now for the first time fully exploit high dose rate delivery, potentially enabling even greater capabilities for sophisticated therapies, including stereotactic radiosurgery (SRS), stereotactic radiotherapy (SRT) and volumetric modulated arc therapy (VMAT).
In the spring of 2013, Kuopio University Hospital (KUH, Kuopio, Finland) will take a leap forward in radiation therapy capabilities when the center begins treating patients with its two new Elekta Infinity(TM) treatment systems equipped with the revolutionary Agility(TM) 160-leaf multileaf collimator (MLC). The two Elekta therapy systems will replace two older generation linear accelerators from Varian Medical Systems. In combination with Agility, the Infinity systems -- specifically designed to deliver fast Volumetric Modulated Arc Therapy (VMAT) -- will enable faster treatments tailored to the profile of the tumor. Agility uses 160 high-speed, 5mm-wide beam-shaping leaves to accurately conform the radiation field to the lesion's shape, and moves the leaves at twice the speed of other MLCs. KUH also has purchased Elekta's Oncentra(R) VMAT and Monaco(R) treatment planning systems. In 2015, KUH will relocate its radiation therapy systems to a new six-bunker radiotherapy department.
| Recently Viewed | |||
| EKTAB:SS | kr102.30 SEK | +0.90 | |
| Company | Last | Change |
| Accuray Inc | $5.55 USD | +0.04 |
| American Shared Hospital Services | $1.99 USD | +0.06 |
| IsoRay Inc | $0.53 USD | +0.01 |
| MRI Interventions Inc | $1.15 USD | -0.03 |
| Varian Medical Systems Inc | $70.14 USD | +0.26 |
| View Industry Companies | ||
Industry Analysis
EKTAB
Industry Average
| Valuation | EKTAB | Industry Range |
| Price/Earnings | 35.6x |
|
| Price/Sales | 3.8x |
|
| Price/Book | 7.8x |
|
| Price/Cash Flow | 34.4x |
|
| TEV/Sales | 3.1x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Northglenn, CO | Office DepotPosted: Mar 01
Sponsored Financial Commentaries
Sponsored Links
To contact ELEKTA AB-B SHS, please visit www.elekta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








